Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.

Rizzo M, Abate N, Chandalia M, Rizvi AA, Giglio RV, Nikolic D, Marino Gammazza A, Barbagallo I, Isenovic ER, Banach M, Montalto G, Li Volti G

The Journal of clinical endocrinology and metabolism13 Nov 2014Cited by 93 (Europe PMC)

PMID25393640PMCIDPMC4318909DOI10.1210/jc.2014-2291PepBankPUB-25393640

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes on metformin, 2 months of add-on liraglutide significantly lowered HbA1c from baseline.
In plain wordsIn adults with type 2 diabetes taking metformin, adding liraglutide for 2 months lowered HbA1c.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 20
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg/d for 2 wk, followed by 1.2 mg/d · subcutaneous · 2 monthsAs given in this study (human).
Measurements
HbA1c
8.5 to 7.5%
before vs after liraglutide
Source sentences
Summary
The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 ± 0.4 vs 7.5 ± 0.4%, P < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy.
Summary · context
Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months.
Report a problemFND-2539364001
02HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes on metformin, add-on liraglutide increased plasma ghrelin concentrations from baseline.
In plain wordsIn adults with type 2 diabetes taking metformin, adding liraglutide raised plasma ghrelin levels.
Peptide
Liraglutide
Outcome
IncreasePlasma ghrelin
Study
n = 20
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
0.6 mg/d for 2 wk, followed by 1.2 mg/d · subcutaneous · 2 monthsAs given in this study (human).
Source sentences
Summary
plasma ghrelin and glutathione concentrations increased (8.2 ± 4.1 vs 13.6 ± 7.3 pg/ml, P = .0007 and 0.36 ± 0.06 vs 0.44 ± 0.07 nmol/ml, P = .0002, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy.
Summary · context
Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months.
Report a problemFND-2539364002
03HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes on metformin, add-on liraglutide increased plasma glutathione concentrations from baseline.
In plain wordsIn adults with type 2 diabetes taking metformin, adding liraglutide raised plasma glutathione, an antioxidant marker.
Peptide
Liraglutide
Outcome
IncreasePlasma glutathione
Study
n = 20
Outcome group
Oxidative stress · Cardiovascular
Studied dose
0.6 mg/d for 2 wk, followed by 1.2 mg/d · subcutaneous · 2 monthsAs given in this study (human).
Source sentences
Summary
plasma ghrelin and glutathione concentrations increased (8.2 ± 4.1 vs 13.6 ± 7.3 pg/ml, P = .0007 and 0.36 ± 0.06 vs 0.44 ± 0.07 nmol/ml, P = .0002, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy.
Summary · context
Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months.
Report a problemFND-2539364003
04HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes on metformin, add-on liraglutide decreased serum lipid hydroperoxides from baseline.
In plain wordsIn adults with type 2 diabetes taking metformin, adding liraglutide lowered a blood marker of oxidative stress.
Peptide
Liraglutide
Outcome
DecreaseSerum lipid hydroperoxides
Study
n = 20
Outcome group
Oxidative stress · Cardiovascular
Studied dose
0.6 mg/d for 2 wk, followed by 1.2 mg/d · subcutaneous · 2 monthsAs given in this study (human).
Source sentences
Summary
whereas serum lipid hydroperoxides and HO-1 decreased (0.11 ± 0.05 vs 0.04 ± 0.07 pg/ml, P = .0487 and 7.7 ± 7.7 vs 3.6 ± 1.8 pg/ml, P = .0445, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy.
Summary · context
Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months.
Report a problemFND-2539364004
05HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes on metformin, add-on liraglutide decreased serum HO-1 from baseline.
In plain wordsIn adults with type 2 diabetes taking metformin, adding liraglutide lowered serum heme oxygenase-1.
Peptide
Liraglutide
Outcome
DecreaseSerum heme oxygenase-1 (HO-1)
Study
n = 20
Outcome group
Oxidative stress · Cardiovascular
Studied dose
0.6 mg/d for 2 wk, followed by 1.2 mg/d · subcutaneous · 2 monthsAs given in this study (human).
Source sentences
Summary
whereas serum lipid hydroperoxides and HO-1 decreased (0.11 ± 0.05 vs 0.04 ± 0.07 pg/ml, P = .0487 and 7.7 ± 7.7 vs 3.6 ± 1.8 pg/ml, P = .0445, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy.
Summary · context
Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months.
Report a problemFND-2539364005
06HumanNon-randomized trialMechanism
In adults with type 2 diabetes on metformin, the changes under liraglutide were not correlated with changes in fasting glycemia or HbA1c.
In plain wordsIn adults with type 2 diabetes taking metformin, the changes seen with liraglutide were not linked to changes in blood sugar or HbA1c.
Peptide
Liraglutide
Outcome
No significant changeCorrelation of ghrelin, oxidative stress and HO-1 changes with glycemia
Study
n = 20
Outcome group
Oxidative stress · Metabolic and weight
Studied dose
0.6 mg/d for 2 wk, followed by 1.2 mg/d · subcutaneous · 2 monthsAs given in this study (human).
Source sentences
Summary
These changes were not correlated with changes in fasting glycemia or HbA1c.
2 context sentences(design, population, supporting numbers)
Summary · context
A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy.
Summary · context
Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months.
Report a problemFND-2539364006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT01715428

Liraglutide and Cardio-Metabolic Risk Markers

University of Palermon = 300Jun 2012 to Dec 2015

Type-2 Diabetes

Trial page ClinicalTrials.govUpdated 22 Nov 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.